Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis.
Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis. J Rheumatol. 2019 Nov 01;: Authors: Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS Abstract Psoriatic arthritis (PsA) affects up to 30% of patients with psoriasis and may include musculoskeletal manifestations such as enthesitis. Enthesitis is associated with joint damage, and early detection and treatment are essential to management of the disease. Traditionally assessed by clinical examination and conventional radiography, entheseal inflammation can now be more accurately assessed earlier in the disease using techniques such as ultrasound, magnetic resonance imaging, computed tomography, and molecular imaging. However, there is little consensus on the optimum definition for diagnosing enthesitis in PsA or on the ideal scoring system for measuring response to treatment. This review aims to summarize the benefits and limitations of different imaging modalities in the assessment of enthesitis. It also proposes that adoption of standardized definitions and validation of scoring systems and imaging techniques in clinical trials will allow the efficacy of new treatment options to be assessed more accurately. PMID: 31676700 [PubMed - as supplied by publisher]
CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents. PMID: 33034437 [PubMed - as supplied by publisher]
Conclusion: This large study did not support that a high intake of fibre and/or a low intake of meat had a high impact on the risk of late-onset CID. PMID: 33029091 [PubMed - in process]
CONCLUSIONS: In this review, we include a study of the new anti-IL-17 biological agents (secukinumab, ixekizumab, and bromalizumab ) used for moderate-to-severe psoriasis and psoriatic arthritis treatment in clinical practice, as well as pivotal trials with bimekizumab. We study the relationship of these biological agents and the appearance of candidiasis in its various clinical forms. PMID: 33026212 [PubMed - as supplied by publisher]
Cyclic adenosine monophosphate (cAMP) acts as a second messenger for intercellular signal transduction. In particular, the cAMP-PKA-CREB pathway is crucial for the regulation of inflammatory genes in immune cells. To target that pathway in immune responses, phosphodiesterase 4 (PDE4) inhibitors that inhibit the conversion of cAMP to AMP were developed.  Apremilast, a PDE4 inhibitor, was approved for the oral treatment of psoriasis and psoriatic arthritis. Additionally, a modest efficacy of apremilast for atopic dermatitis (AD) has been shown. Crisaborole, another PDE4 inhibitor, was approved for the topical treatment...
ConclusionOur study can imply that IL ‐17A is a valuable, useful and low‐cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA (nr‐axial SpA) psoriatic patients that helps early management and prevent progressive axial involvement and disabilities.
CONCLUSION: In this US real-world cohort, most patients had multidomain disease presentations, which was associated with worse disease activity, QOL, and work productivity measures. This study highlights the heterogeneity of PsA and the importance of assessing all PsA domains for optimizing disease management. PMID: 33004532 [PubMed - as supplied by publisher]
Publication date: Available online 2 October 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Tsen-Fang Tsai, Tsu-Yi Hsieh, Ching-Chi Chi, Chung-Tei Chou, Lin-Fen Hsieh, Hsin-Hua Chen, Rosaline Chung-Yee Hui, Chih-Hung Lee, Chin-Hsiu Liu, Hwa-Chang Liu, Kai-Jieh Yeo, Chun-Hsiung Chen, Hung-An Chen, Ying-Chou Chen, Yi-Ju Chen, Hsien-Yi Chiu, Ji-Chen Ho, Yu-Huei Huang, Po-Ju Lai, Woan-Ruoh Lee
Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News
ology Association (TRA) and the Taiwanese Association for Psoriasis and Skin Immunology (TAPSI) Abstract In Taiwan, the incidence and prevalence of psoriatic arthritis (PsA) have risen significantly in recent years. Moreover, data from the Taiwan National Health Insurance Research Database (NHIRD) show that more than 85% of PsA patients are treated with just non-steroidal anti-inflammatory drugs (NSAIDs) and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Taiwanese clinicians have also expressed concerns regarding uncertainties in the diagnosis of PsA and the delayed, interrupted, and/...
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...